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Many mood disorder patients need analgesics due to increased pain sensitivity. Recent 
studies have suggested that non-steroidal anti-inflammatory drugs (NSAIDs) may inhibit 
antidepressant treatment, which requires replication before clinical recommendations.  
Methods 
The Clinical and Health Outcomes Initiatives in Comparative Effectiveness for Bipolar 
Disorder Study randomized participants to 6 months lithium or quetiapine treatment. Use of 
NSAIDs and paracetamol was assessed throughout the study period and psychopathology 
measured with the Clinical Global Impression Scale for bipolar disorder (CGI-BP) and Bipolar 
Inventory of Symptoms Scale (BISS). The effects of NSAIDs and paracetamol on treatment 
outcome were examined using mixed effects linear regression adjusted for age, gender, 
BMI, smoking-status, exercise, and somatic diseases.  
Results 
Among 482 participants, 177 (36.7%) used NSAIDs and/or paracetamol during the study. 
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outcome with lithium or quetiapine at any time-point during 6 month treatment on the 
overall CGI-BP (β=0.001 (95%-CI=-0.01-0.01), p=0.87), the BISS (β=0.01 (95%-CI=-0.17-0.15), 
p=0.91), nor the CGI-BP subscales for depression or mania. Users of NSAIDs only (n=76), 
paracetamol only (n=62), and users of both NSAIDs and paracetamol (n=39) showed no 
statistical difference compared to non-users (all p>0.3).  
Conclusions 
This is the first trial to show that use of NSAIDs and paracetamol, alone or in combination, 
does not affect lithium- or quetiapine-based bipolar disorder mood-stabilizing treatment 
outcomes. Prior studies have suggested that NSAIDs may inhibit antidepressant treatment, 
whereas our results support findings indicating no detrimental effects of NSAIDs or 
paracetamol on affective disorder treatment.  
 
Introduction:  
Treatment outcomes in affective disorders, i.e. unipolar and bipolar depression, are often 
suboptimal.[1] This is further complicated by the presence of comorbid occurring somatic 
diseases (e.g. painful states) which have been associated with worse treatment effects.[2,3] 
These issues represent important clinical challenges as comorbid diseases necessitate 
relevant treatment, potentially leading to polypharmacy. Therefore, it is noteworthy that 
recent studies, including animal models and clinical data, suggested that concomitant use of 
non-steroidal anti-inflammatory drugs (NSAIDs) may worsen the outcomes of selective 
serotonin reuptake inhibitor (SSRI) treatment.[4,5] However, these findings are 
controversial,[6] and since NSAIDs are frequently used among individuals taking SSRIs,[7] 
these associations represent findings with a potential impact on clinical decision-making and 
thus, need replication.  
Interestingly, a more recent study including 811 depressed patients from the Genome-
Based Therapeutics Drugs for Depression (GENDEP) trial found no change in treatment 
outcome among patients using NSAIDs during 12 weeks treatment with the SSRI 
escitalopram or the tricyclic antidepressant (TCA) nortriptyline.[8] Furthermore, two 
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NSAIDs, indicating the safety of several frequently used NSAIDs when used in combination 
with SSRIs [7] or lithium. [9] Other studies have actually indicated that short-term, 
adjunctive NSAID treatment may yield additional antidepressant treatment effects.[10,11] 
Finally, it has been suggested that the findings associating NSAIDs with poorer 
antidepressant treatment response may be explained by confounding factors, e.g. residual 
confounding,[5,6] emphasizing the need for further clinical trials investigating the 
interaction between these frequently used drugs among patients with affective disorder.  
Due to the high clinical relevance, the abovementioned associations have to be investigated 
in different populations of patients with affective disorders. To date, no clinical studies have 
investigated whether concomitant use of NSAIDs may affect treatment of patients with 
bipolar disorder. Thus, we prospectively investigated whether use of NSAIDs and 
paracetamol may affect mood-stabilizing treatment among patients with bipolar disorder in 
the Clinical and Health Outcomes Initiatives in Comparative Effectiveness for Bipolar 
Disorder Study (Bipolar CHOICE) study. This study is ideal to examine the association of 
NSAIDs with treatment outcomes as it was a generalizable, highly representative sample of 
individuals with bipolar disorder (e.g., participants were not excluded if they had comorbid 
medical conditions), receiving one of two pharmacotherapy intervention (lithium or 
quetiapine) commonly used to treat the condition with long follow-up. 
 
Materials and Methods:  
Setting 
The present study represents a secondary analysis from the Bipolar CHOICE study.[12] 
Bipolar CHOICE was a 6-month multi-site, randomized comparative effectiveness trial, 
comparing lithium (a classic mood-stabilizer) to quetiapine (a commonly used 
antipsychotic), combined with other guideline-informed medications for bipolar disorder 
(but not with one another) consistent with typical clinical practice. Subjects provided verbal 
and written informed consent prior to participation in the presence of the study clinician. 
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For Bipolar CHOICE, 692 patients aged between 18 and 62 years were screened, whereof 
482 were randomized. Limited inclusion and exclusion criteria were utilized to maximize 
heterogeneity of the sample and generalizability of the results, but participants were 
required to have a DSM-IV-TR bipolar I or bipolar II diagnosis and to be at least mildly 
symptomatic (Clinical Global Impression Scale for Bipolar Disorder (CGI-BP) ≥3 [13]) at study 
entry.  
Psychiatric and substance use diagnoses were determined using the extended Mini-
International Neuropsychiatric Interview, an electronic version of a validated structured 
diagnostic interview.[14] Psychiatric symptom severity was measured with the CGI-BP [13] 
and the Bipolar Inventory of Symptoms Scale (BISS).[15,16] The CGI-BP has an overall illness 
severity rating as well as subscales for depression and mania severity. All participants were 
rated with the above mentioned symptom scales at baseline as well as over the 6 month 
study period (i.e., 8 follow-up visit). Clinical interviews obtained demographic information 
and medical history.  
 
NSAID and paracetamol use 
At baseline and the 8 follow-up visits, the medication doses and dose changes were 
captured on the Medication Recommendation Tracking Form.[17] In agreement with prior 
studies,[4,5,8] we considered NSAIDs and paracetamol separately and included the same 
NSAID compounds: acetylsalicylic acid (aspirin), celecoxib, diclofenac, ibuprofen, naproxen, 
indomethacin, and meloxicam. Paracetamol included acetaminophen and its derivatives, 
but excluded opiates. Since NSAIDs and paracetamol often are used for short periods of 
time or at low dosages (e.g., acetylsalicylic acid for cardiovascular prevention), we assessed 
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anti-inflammatory and pain-relieving properties. Dosage of each drug was coded with 
reference to the effective dose range recommended by the World Health Organization 
(WHO) (http://www.whocc.no). The dose of at least the minimum recommended 
therapeutic dose at ≥1 visit was considered therapeutically significant, which was used in 
prior studies.[4,5,8] We coded individuals as users if they had used NSAIDs or paracetamol 
at this significant dose at any point during the study. In order to investigate the compounds 
in more detail, we divided users into whether they had used NSAIDs only, paracetamol only, 
or both NSAIDs and paracetamol.  
 
Statistical analysis 
We included baseline information on the following covariates which are likely to have an 
impact on treatment outcome and the propensity to receive NSAIDs or paracetamol: age, 
gender, body mass index (BMI), current smoking, regular exercise (i.e. at least once weekly), 
and the medical conditions of diabetes, hypertension and hyperlipidemia. To explore the 
relationship between use of NSAIDs and/or paracetamol with the above mentioned 
covariates, we performed logistic regression analyses and report odds ratios (OR) including 
95% confidence intervals (95%-CI). 
To investigate the effect of NSAID/paracetamol use on mood-stabilizing treatment outcome, 
we performed mixed effects linear regression models to assess differences in treatment 
outcome between NSAID/paracetamol users and non-users and report β-coefficients 
including 95%-CI. These models allow inclusion of all relevant covariates across repeated 
measurements and efficiently handle missing data.[18] We compared users of 
NSAIDs/paracetamol with non-users on the overall treatment effect after 6 months and on 
the treatment effect at every visit during the study period. The dependent variables were 
the total scores on the included rating scales (overall CGI-BP, BISS, CGI-BP subscales for 
depression and mania) at up to 9 assessments (i.e., baseline and 8 follow-up visits) during 
the 6 month study period. We performed all analyses in an unadjusted model and also in a 
model adjusting for all covariates to distinguish whether an effect of NSAIDs or paracetamol 
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For the primary analyses, we investigated whether individuals with use of NSAIDs or 
paracetamol differed from non-users on the overall treatment outcome, measured by the 
overall CGI-BP, the CGI-BP subscales for depression and mania, and the BISS scale. 
Secondary analyses comprised all analyses among individuals randomized to lithium 
respectively quetiapine. Third, to be able to distinguish between NSAIDs and paracetamol in 
more detail, we performed analyses among individuals using NSAIDs only, individuals using 
paracetamol only, and individuals using both NSAIDs and paracetamol, all compared to non-
users. Finally, we performed interaction analyses between NSAID/paracetamol use and the 
two treatment regimens (i.e., lithium and quetiapine) to further explore differences 
between the two study drugs. All analyses were performed using STATA 14.0.  
 
Sensitivity analyses 
First, we performed age and gender specific analyses. Secondly, since painful states (the 
indication for NSAID and paracetamol treatment) often are accompanied by inflammatory 
processes, we included the baseline white blood cell count (WBC). At study entry, a fasting 
blood draw assessed WBC, expressed in International units, i.e. x109/L. A WBC measure 
≥10x109/L (i.e., leukocytosis), indicates an inflammatory response. We investigated whether 
NSAID/paracetamol use changed treatment outcome among individuals with a baseline 
WBC ≥10x109/L respectively among individuals with a baseline WBC <10x109/L. Third, we 
performed sensitivity among lithium users who were treated within the therapeutic range 
(0.6-1.2 mMol/L) during the study period. Finally, the main analyses included non-users with 
missing data concerning co-medication at ≥1 study visits (N=105 (34.4%) out of the 305 non-
users), and we investigated whether the exclusion of the non-users with missing data 
affected our results. 
 
Results 
Among 482 Bipolar CHOICE participants, 177 (36.7%) used NSAIDs or paracetamol during 
the study period, (76 (15.8%) used NSAIDs only, 62 (12.8%) used paracetamol only, and 39 
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NSAID/paracetamol users and non-users are depicted in Table 1. When investigating the 
relationship between NSAID/paracetamol use and potential confounders, we found that 
users, compared to non-users, were more likely to be female and to have a diagnosis of 
hypertension, but less likely to have a diagnosis of diabetes.  
 
Effect of NSAID and/or paracetamol use on mood-stabilizing treatment outcome 
A total of 382 patients completed all 9 study visits. During 6 months of mood-stabilizing 
treatment, the fully adjusted mixed effects linear regression models showed that all 482 
participants decreased in overall CGI-BP by a β-coefficient of -0.05 per week (95%-CI=-0.06; -
0.04) (Table 2). Users of NSAIDs or paracetamol decreased in overall CGI-BP by a β of -0.052 
per week (95%-CI=-0.06; -0.044), whereas non-users decreased by a β of -0.051 per week 
(95%-CI=-0.058; -0.044). All results were significant (p<0.001). When comparing users of 
NSAIDs or paracetamol to non-users regarding the decrease in overall CGI-BP, we found no 
difference as indicated by a β of -0.001 (95%-CI=-0.01; 0.01), p=0.87). Furthermore, we 
found no differences between users and non-users on the BISS (β=0.01, 95%-CI=-0.17; 0.15, 
p=0.91) nor on the CGI-BP subscales for depression (p=0.86) or mania (p=0.51). In addition, 
we found no significant differences between NSAID/paracetamol users and non-users at any 
time point during the 6 month follow-up (Figure 1). All the above mentioned results were 
similar in the unadjusted models (results not shown).  
Second, we investigated whether NSAID/paracetamol treatment affected the specific mood-
stabilizing treatment to confirm the above mentioned negative results. When comparing 
NSAID/paracetamol users to non-users, we found that there was not a different treatment 
response among 240 individuals randomized to lithium or among 242 individuals 
randomized to quetiapine, as tested with the overall CGI-BP, BISS, and CGI-BP subscales for 
depression and mania (all p>0.05 as shown in Table 3). During 6 month of treatment with 
lithium respectively quetiapine, we found no significant differences between 
NSAID/paracetamol users and non-users at any time point on the CGI-BP or on the BISS 
(Figure 1). Furthermore, we performed interaction analyses between NSAID/paracetamol 
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response as measured with the overall CGI-BP (p=0.53) and the BISS (p=0.42). The 
unadjusted models showed very similar results (results not shown).  
 
NSAIDs only, paracetamol only, and the combination of NSAIDs and paracetamol 
To further investigate the effects of the specific compounds, we performed analyses among 
individuals using NSAIDs only (N=76), individuals using paracetamol only (N=62), and 
individuals using both NSAIDs and paracetamol (N=39). Compared to non-users of NSAIDs or 
paracetamol, we found no significant difference in 6 month treatment outcome for these 
subgroups on the overall CGI-BP and BISS or on the CGI-BP subscales for depression or 
mania (Table 4). In addition, within these three subgroups, we found no significant 
differences among individuals randomized to lithium or quetiapine, or at any time point 
during the 6 month study period (all p>0.05, results not shown).  
 
Sensitivity analyses 
We found no differences in age-specific or gender separate analyses (all p>0.05, results not 
shown). In addition, use of NSAIDs and/or paracetamol did not affect lithium or quetiapine 
treatment among 50 individuals with a baseline WBC≥10x109/L, indicating an inflammatory 
response, or among 432 individuals with a baseline WBC<10x109/L (all p>0.05, results not 
shown). Furthermore, of the 240 individuals randomized to lithium, a total of 104 (43.3%) 
were within therapeutic ranges during the study period, whereof 45 (43.2%) used NSAIDs or 
paracetamol. Analyses on this subgroup (N=104) showed no differences in treatment effects 
between users and non-users of NSAIDs/paracetamol with no differences at any time point 
during the 6 month study period (all p>0.05, results not shown). Finally, we found no 
significant differences between NSAID/paracetamol users and non-users after exclusion of 
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NSAIDs and paracetamol are among the most frequently used drugs among individuals with 
affective disorders due to somatic comorbidity and increased pain sensitivity.[7] The present 
study represents the first trial investigating whether NSAIDs and paracetamol negatively 
affect mood-stabilizing treatment in bipolar disorder. We have attempted to replicate 
findings from previous studies that reported conflicting results regarding the safety of 
NSAIDs and paracetamol during antidepressant treatment.[4,5,8] Within the Bipolar CHOICE 
trial including 482 patients with bipolar disorder, use of NSAIDs and paracetamol, compared 
to non-use, was not associated with differing treatment outcomes of mood-stabilizing 
treatment. Individuals using NSAIDs and/or paracetamol (N=177; 36.7%) were more likely to 
be female and differed regarding somatic comorbidity. Despite these differences, NSAIDs 
and paracetamol, used alone or in combination with each other, did not affect treatment 
outcome with lithium or quetiapine at any time during the 6 month follow up period. The 
results were similar in the unadjusted and adjusted models. This finding is particularly 
noteworthy as we only included NSAID and paracetamol at therapeutic pain-relieving doses, 
used different symptom scales as possible outcomes, adjusted for important covariates, and 
conducted several sub-analyses. Hence, our results support findings [8,9] suggesting the 
safety of NSAIDs and paracetamol among individuals treated for their affective disorder. 
Since the Bipolar CHOICE study was a pragmatic trial designed to maximize generalizability, 
our results are relevant and representative for everyday clinical work.  
 
Effects of NSAIDs and paracetamol on treatment of affective disorders 
Given that pain-related somatic comorbidity is common in mood disorders requiring the 
need for pain-relieving medications, it is important to examine the potential beneficial or 
harmful combination of NSAIDS and psychiatric medications in clinical trials. Recent studies 
included animal models and clinical data to investigate whether use of NSAIDs affects SSRI 
treatment.[4,5] The results associated NSAIDs with worse outcomes of SSRI treatment, and 
the authors concluded that “clinicians should carefully balance the therapeutic benefits of 
antiinflammatory agents versus the potentially negative consequences of antagonizing the 
therapeutic efficacy of antidepressant agents in patients suffering from depression”.[4] 
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other affective disorders, thus requiring caution concerning clinical recommendations. 
Indeed, within the GENDEP study, NSAID use was not associated with different treatment 
effects among 811 patients with depression.[8] The authors found no differences in 
treatment outcome among individuals randomized to 12 weeks treatment with the SSRI 
escitalopram or the tricyclic antidepressant (TCA) nortriptyline. Furthermore, a 
pharmacoepidemiological study found that NSAID use during lithium treatment was not 
associated with clinical deterioration.[9] Finally, Gallagher et al. suggested that their results 
associating NSAIDs with poorer antidepressant effects might be due to confounding factors, 
emphasizing cautiousness, particularly regarding clinical recommendations based on their 
results.[5] This cautiousness has also been emphasized by other researchers.[6]  
Other studies have actually indicated that targeted short-term NSAID treatment may 
improve the treatment outcomes when used as add-on to antidepressants [19] or mood-
stabilizers.[10] Indeed, it has been discussed that specific subgroups of patients with 
affective disorders, e.g. those with increased pro-inflammatory biomarkers, may benefit of 
additional NSAID treatment.[11,20,21]  
Despite these potential beneficial treatment effects in specific subgroups, the far more 
frequent occurring clinical challenge is the need for pain-relieving treatment because of 
comorbid somatic states. Therefore, it is important that our results support previous 
findings [8] suggesting that NSAIDs and paracetamol does not negatively impact the 
treatment of affective disorders. Nevertheless, NSAIDs have been associated with side 
effects, such as an increased risk for gastrointestinal bleeding [22] and cardiovascular 
events.[23] Hence, clinicians should always balance the beneficial pain-relieving effects of 
NSAIDs and paracetamol against the risk for side effects for each patient individually.  
 
Strengths and limitations 
The Bipolar CHOICE study was a pragmatic trial designed to maximize generalizability, thus 
representing patients with bipolar disorder seen in everyday clinical practice. In addition, we 
were able to adjust for age, gender, BMI, smoking-status, exercise, and specific somatic 
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propensity for receiving NSAIDs and paracetamol. Furthermore, NSAID and paracetamol use 
was identified at every study visit,[17] minimizing the risk for missing the use of these 
compounds, i.e. minimizing the risk for misclassification. Finally, the definition of NSAID and 
paracetamol use, including the analytical approaches, were in agreement with prior studies 
investigating this aspect [4,5,8] highlighting the comparability of our findings.  
Our findings should also be considered within the limitations of this study. First, with a 
larger sample size it would have been possible to detect potential small effect sizes. Second, 
we did not measure all possible confounding variables, although we did include several 
clinically relevant covariates. For example, we had no measure on chronic pain symptoms, 
which could influence both NSAID use and treatment outcome. Third, patients with bipolar 
disorder often require treatment for several years and the study period of 6 months in the 
present study limited our ability to address longer-term effects. Finally, data were collected 
within the context of a randomized study which does reduce the generalizability of these 




Among 482 participants from the Bipolar CHOICE study, a total of 177 (37%) used NSAIDs 
and/or paracetamol at therapeutic doses during 6 month treatment with lithium or 
quetiapine. Use of NSAIDs and paracetamol, alone or in combination, did not affect lithium 
or quetiapine treatment response at any time point during the 6 month mood-stabilizing 
treatment. Thus, the present study is the first to investigate this clinically important aspect 
among patients with bipolar disorder, and our results support prior findings suggesting that 
use of NSAIDs and paracetamol does not inhibit the efficacy of psychotropic treatment in 
affective disorders. The clinical importance of our findings is further emphasized since these 
compounds are among the most frequently used medications among patients with affective 
disorders due to the high prevalence of somatic comorbidity and by the generalizability of 
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Figure 1 CGI-BP and BISS scores during 6 months of follow-up* among 240 individuals randomized to 
lithium (top two figures) respectively 242 individuals randomized to quetiapine (bottom two figures). 
Lithium (N = 240, whereof N = 98 (40.8%) used NSAIDS or paracetamol. 
There were no significant differences between users of NSAIDs/paracetamol and non-users at any 
time point (all p > 0.05). Abbreviations: CGI-BP= Clinical Global Impression for Bipolar Disorder; BISS= 
Bipolar Inventory Symptom Scale; NSAID= Non-steroidal anti-inflammatory drug. 
*All mixed effects linear regression analyses were adjusted for: age, gender, body mass index (BMI), 
current smoking, regular exercise (i.e. at least once weekly), and the medical conditions of diabetes, 
hypertension and hyperlipidemia. 
 
 
Table 1: Baseline information for 482 patients with bipolar disorder, divided into non-users1 and 
users1 of NSAIDs or paracetamol.  
 Total Non-users of 
NSAIDs or 
paracetamol1 
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Gender     
Male 199 (41.3) 139 (45.6) 60 (33.9) 1.0 (ref.) 
Female 283 (58.7)  166 (54.4) 117 (66.1) 1.84 (1.15; 2.93) 
Mean Age (IQR) 38.9 (28; 49) 38.2 (28; 47) 40.1 (30; 50)  
Age-group     
≤30 153 (31.7) 105 (34.4) 48 (27.1) 1.0 (ref.) 
31-45 167 (34.7) 103 (33.8) 64 (36.2) 1.13 (0.63; 2.03) 
≥45 162 (33.6) 97 (31.8) 65 (36.7) 1.06 (0.58; 1.93) 
Current smoking     
No 233 (48.3) 155 (50.8) 78 (27.7) 1.0 (ref.) 
Yes 249 (51.7) 150 (49.2) 99 (72.3) 1.15 (0.69; 1.91) 
Weekly exercise     
No 195 (40.2) 118 (38.5) 77 (43.2) 1.0 (ref.) 
Yes 287 (59.8) 187 (61.5) 100 (56.8) 0.89 (0.56; 1.42) 
BMI     
<20 25 (5.2) 16 (5.3) 9 (5.1) 1.0 (ref.) 
20-24.99 107 (22.2) 65 (21.5) 42 (23.9) 1.11 (0.39; 3.14) 
25-29.99 134 (27.8) 90 (29.8) 44 (25.0) 0.65 (0.23; 1.85) 
≥30 212 (44.0) 131 (43.4) 81 (46.0) 0.92 (0.34; 2.52) 
Medical conditions     
Diabetes 30 (6.2) 21 (6.9) 9 (5.1) 0.24 (0.07; 0.80) 
Hypertension 90 (18.7) 44 (14.4) 46 (26.0) 1.96 (1.06; 3.63) 
Hyperlipidemia 103 (21.4) 56 (18.4) 47 (26.6) 1.29 (0.71; 2.32) 
Diagnoses     
Current manic 
episode 
















48 (10.0) 35 (11.5) 13 (7.3) 0.65 (0.25; 1.71) 
None of the 
above 
(subthreshold) 
75 (15.6) 49 (16.1) 26 (14.7) 0.90 (0.53; 1.50) 
Abbreviations: NSAID: Non-steroidal anti-inflammatory drug.  
1 Users are individuals who used NSAIDs or paracetamol at significant dosages at ≥1 visit during the 
follow-up period.  
2 We performed logistic regression analyses comparing users of NSAIDs and/or paracetamol versus 
non-users and included all the covariates mentioned in Table 1 in the final model. We report odds 
ratios (OR) including 95% confidence intervals (95%-CI). 
 
Table 2: Effect of additional use1 of NSAIDs or paracetamol versus non-users1 during 24 weeks of 
mood-stabilizing treatment: results of mixed effects linear regression analyses2.  
 Baseline Estimated change per week Estimated 
difference 
 Total Non-users1 Users1 Total Non-
users1 
Users1 Users1 vs. 
non-
users1 








NSAIDs or paracetamol (N=177) 






















































Abbreviations: β: Regression coefficient; 95%-CI: 95% Confidence Interval; SD: Standard deviation; 
CGI-BP = Clinical Global Impression Scale for Bipolar Disorder; NSAID: Non-steroidal anti-
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A negative β indicates better treatment effect among users of NSAIDs or paracetamol, whereas a 
positive β indicates better treatment effect among non-users.  
1 Users are individuals who used NSAIDs or paracetamol at significant dosages at ≥1 visit during the 
follow-up period.  
2 All analyses were adjusted for: age, gender, body mass index (BMI), current smoking, regular 




Table 3: Effect of additional use1 of NSAIDs or paracetamol versus non-users1 during 24 weeks of 
treatment among individuals randomized to lithium or quetiapine: results of mixed effects linear 
regression analyses2.  
 Lithium (n = 240) Quetiapine (n = 242)  
 β (95%-CI) p-value β (95%-CI) p-value 
CGI-BP overall -0.007 (–0.031; 0.016) 0.53 –0.008 (–0.036; 0.019) 0.56 
CGI-BP depression –0.0055 (–0.030; 0.019) 0.66 –0.020 (–0.049; 0.0097) 0.19 
CGI-BP mania –0.016 (–0.038; 0.0056) 0.15 0.007 (–0.019; 0.033) 0.60 
BISS  –0.18 (–0.58; 0.23) 0.39 –0.27 (–0.74; 0.19) 0.25 
Abbreviations: β: Regression coefficient; 95%-CI: 95% Confidence Interval; CGI-BP = Clinical Global 
Impression Scale for Bipolar Disorder; NSAID: Non-steroidal anti-inflammatory drug; BISS: Bipolar 
Inventory of Symptoms Scale.  
A negative β indicates better treatment effect among users of NSAIDs or paracetamol, whereas a 
positive β indicates better treatment effect among non-users.  
1 Users are individuals who used NSAIDs or paracetamol at significant dosages at ≥1 visit during the 
follow-up period.  
2 All analyses were adjusted for: age, gender, body mass index (BMI), current smoking, regular 
exercise (i.e. at least once weekly), and the medical conditions of diabetes, hypertension and 
hyperlipidemia.  
 
Table 4: Effect of additional use1 of NSAIDs only, paracetamol only, or the combination versus non-
users1 during 24 weeks of mood-stabilizing treatment: results of mixed effects linear regression 
analyses2.  











Users1 Users1 vs. 
non-
users1 








NSAIDs only (N = 76) 
CGI-BP 
overall 
4.5 ± 0.9 4.5 ± 0.9 4.5 ± 0.9 -0.05 (-0.06; 
-0.04), p < 
0.001 
-0.05 (-0.06; 




p < 0.001 
-0.006 (-0.022; 




4.2 ± 1.1 4.2 ± 1.2 4.3 ± 1.1 -0.05 (-0.06; 
-0.04), p < 
0.001 
-0.05 (-0.06; 
-0.04), p < 
0.001 
-0.05 (-0.07; 
-0.04), p < 
0.001 
-0.005 (-0.023; 
0.13), p = 0.58 
CGI-BP 
mania 
3.0 ± 1.3 3.0 ± 1.3 2.9 ± 1.1 -0.03 (-
0.035; -








0.02), p < 
0.001 
-0.003 (-0.02; 
0.13), p = 0.67 
BISS 56.6 ± 19.2 56.2 ± 20.1 54.4 ± 19.8 -0.87 (-0.96; 
-0.78), p < 
0.001 
-0.87 (-1.01; 
-0.73), p < 
0.001 
-0.86 (-1.09; 
-0.63), p < 
0.001 
0.003 (-0.29; 
0.29), p = 0.98 
Paracetamol only (N=62) 
CGI-BP 
overall 
4.5 ± 0.9 4.5 ± 0.9 4.6 ± 0.8 -0.05 (-0.06; 
-0.04), p < 
0.001 
-0.05 (-0.06; 
-0.04), p < 
0.001 
-0.05 (-0.06; 
-0.03), p < 
0.001 
0.006 (-0.012; 
0.24), p = 0.49 
CGI-BP 
depression 
4.2 ± 1.1 4.2 ± 1.2 4.3 ± 1.1 -0.05 (-0.06; 
-0.04), p < 
0.001 
-0.05 (-0.06; 
-0.04), p < 
0.001 
-0.04 (-0.06; 
-0.02), p < 
0.001 
0.009 (-0.01; 
0.28), p = 0.36 
CGI-BP 
mania 
3.0 ± 1.3 3.0 ± 1.3 3.2 ± 1.1 -0.03 (-
0.035; -








0.021), p < 
0.001 
-0.005 (-0.022; 
0.12), p = 0.59 
BISS 56.6 ± 19.2 56.2 ± 20.1 57.5 ± 15.3 -0.87 (-0.96; 
-0.78), p < 
0.001 
-0.87 (-1.01; 
-0.73), p < 
0.001 
-0.74 (-0.99; 
-0.48), p < 
0.001 
0.16 (-0.14; 
0.47), p = 0.30 
NSAIDs and paracetamol (N = 39) 
CGI-BP 
overall 
4.5 ± 0.9 4.5 ± 0.9 4.6 ± 0.8 -0.05 (-0.06; 
-0.04), p < 
0.001 
-0.05 (-0.06; 
-0.04), p < 
0.001 
-0.05 (-0.06; 
-0.03), p < 
0.001 
0.0003 (-0.02; 
0.02), p = 0.97 
CGI-BP 
depression 
4.2 ± 1.1 4.2 ± 1.2 4.6 ± 0.9 -0.05 (-0.06; 
-0.04), p < 
0.001 
-0.05 (-0.06; 
-0.04), p < 
0.001 
-0.05 (-0.07; 
-0.03), p < 
0.001 
-0.003 (-0.025; 




3.0 ± 1.3 3.0 ± 1.3 3.2 ± 1.1 -0.03 (-
0.035; -
0.025), p < 
-0.03 (-
0.037; -
0.021), p < 
-0.03 (-
0.048; -
0.018), p < 
-0.006 (-0.026; 
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0.001 0.001 0.001 0.56 
BISS 56.6 ± 19.2 56.2 ± 20.1 63.2 ± 14.4 -0.87 (-0.96; 
-0.78), p < 
0.001 
-0.87 (-1.00; 
-0.73), p < 
0.001 
-0.96 (-1.24; 
-0.68), p < 
0.001 
-0.11 (-0.46; 
0.24), p = 0.54 
Abbreviations: β: Regression coefficient; 95%-CI: 95% Confidence Interval; SD: Standard deviation; CGI-BP = Clinical Global Impression 
Scale for Bipolar Disorder; NSAID: Non-steroidal anti-inflammatory drug; BISS: Bipolar Inventory of Symptoms Scale.  
A negative β indicates better treatment effect among users of NSAIDs or paracetamol, whereas a positive β indicates better treatment 
effect among non-users.  
1 Users are individuals who used NSAIDs or paracetamol at significant dosages at ≥1 visit during the follow-up period.  
2 All analyses were adjusted for: age, gender, body mass index (BMI), current smoking, regular exercise (i.e. at least once weekly), and the 





 Total Non-users of 
NSAIDs or 
paracetamol1 





Total 482 (100) 305 (63.3) 177 (36.7)  
Gender     
Male 199 (41.3) 139 (45.6) 60 (33.9) 1.0 (ref.) 
Female 283 (58.7)  166 (54.4) 117 (66.1) 1.84 (1.15; 2.93) 
Mean Age (IQR) 38.9 (28; 49) 38.2 (28; 47) 40.1 (30; 50)  
Age-group     
≤30 153 (31.7) 105 (34.4) 48 (27.1) 1.0 (ref.) 
31-45 167 (34.7) 103 (33.8) 64 (36.2) 1.13 (0.63; 2.03) 
≥45 162 (33.6) 97 (31.8) 65 (36.7) 1.06 (0.58; 1.93) 
Current smoking     
No 233 (48.3) 155 (50.8) 78 (27.7) 1.0 (ref.) 
Yes 249 (51.7) 150 (49.2) 99 (72.3) 1.15 (0.69; 1.91) 
Weekly exercise     
No 195 (40.2) 118 (38.5) 77 (43.2) 1.0 (ref.) 
Yes 287 (59.8) 187 (61.5) 100 (56.8) 0.89 (0.56; 1.42) 
BMI     
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20-24.99 107 (22.2) 65 (21.5) 42 (23.9) 1.11 (0.39; 3.14) 
25-29.99 134 (27.8) 90 (29.8) 44 (25.0) 0.65 (0.23; 1.85) 
≥30 212 (44.0) 131 (43.4) 81 (46.0) 0.92 (0.34; 2.52) 
Medical conditions     
Diabetes 30 (6.2) 21 (6.9) 9 (5.1) 0.24 (0.07; 0.80) 
Hypertension 90 (18.7) 44 (14.4) 46 (26.0) 1.96 (1.06; 3.63) 
Hyperlipidemia 103 (21.4) 56 (18.4) 47 (26.6) 1.29 (0.71; 2.32) 
Diagnoses     
Current manic 
episode 








303 (62.9) 185 (60.7) 118 (66.7) 1.09 (0.55; 2.14) 
Current mixed 
episode 
48 (10.0) 35 (11.5) 13 (7.3) 0.65 (0.25; 1.71) 
None of the 
above 
(subthreshold) 
75 (15.6) 49 (16.1) 26 (14.7) 0.90 (0.53; 1.50) 
 
 
 Baseline Estimated change per week Estimated 
difference 
 Total Non-users1 Users1 Total Non-
users1 
Users1 Users1 vs. 
non-
users1 








NSAIDs or paracetamol (N=177) 
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depression p<0.001 0.042), 
p<0.001 
p<0.001 p=0.86 




























 Lithium (n = 240) Quetiapine (n = 242)  
 β (95%-CI) p-value β (95%-CI) p-value 
CGI-BP overall -0.007 (–0.031; 0.016) 0.53 –0.008 (–0.036; 0.019) 0.56 
CGI-BP depression –0.0055 (–0.030; 0.019) 0.66 –0.020 (–0.049; 0.0097) 0.19 
CGI-BP mania –0.016 (–0.038; 0.0056) 0.15 0.007 (–0.019; 0.033) 0.60 
BISS  –0.18 (–0.58; 0.23) 0.39 –0.27 (–0.74; 0.19) 0.25 
 
 






Users1 Users1 vs. 
non-
users1 








NSAIDs only (N = 76) 
CGI-BP 
overall 
4.5 ± 0.9 4.5 ± 0.9 4.5 ± 0.9 -0.05 (-0.06; 
-0.04), p < 
0.001 
-0.05 (-0.06; 




p < 0.001 
-0.006 (-0.022; 




4.2 ± 1.1 4.2 ± 1.2 4.3 ± 1.1 -0.05 (-0.06; 
-0.04), p < 
0.001 
-0.05 (-0.06; 
-0.04), p < 
0.001 
-0.05 (-0.07; 
-0.04), p < 
0.001 
-0.005 (-0.023; 
0.13), p = 0.58 
CGI-BP 
mania 
3.0 ± 1.3 3.0 ± 1.3 2.9 ± 1.1 -0.03 (-
0.035; -








0.02), p < 
0.001 
-0.003 (-0.02; 
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BISS 56.6 ± 19.2 56.2 ± 20.1 54.4 ± 19.8 -0.87 (-0.96; 
-0.78), p < 
0.001 
-0.87 (-1.01; 
-0.73), p < 
0.001 
-0.86 (-1.09; 
-0.63), p < 
0.001 
0.003 (-0.29; 
0.29), p = 0.98 
Paracetamol only (N=62) 
CGI-BP 
overall 
4.5 ± 0.9 4.5 ± 0.9 4.6 ± 0.8 -0.05 (-0.06; 
-0.04), p < 
0.001 
-0.05 (-0.06; 
-0.04), p < 
0.001 
-0.05 (-0.06; 
-0.03), p < 
0.001 
0.006 (-0.012; 
0.24), p = 0.49 
CGI-BP 
depression 
4.2 ± 1.1 4.2 ± 1.2 4.3 ± 1.1 -0.05 (-0.06; 
-0.04), p < 
0.001 
-0.05 (-0.06; 
-0.04), p < 
0.001 
-0.04 (-0.06; 
-0.02), p < 
0.001 
0.009 (-0.01; 
0.28), p = 0.36 
CGI-BP 
mania 
3.0 ± 1.3 3.0 ± 1.3 3.2 ± 1.1 -0.03 (-
0.035; -








0.021), p < 
0.001 
-0.005 (-0.022; 
0.12), p = 0.59 
BISS 56.6 ± 19.2 56.2 ± 20.1 57.5 ± 15.3 -0.87 (-0.96; 
-0.78), p < 
0.001 
-0.87 (-1.01; 
-0.73), p < 
0.001 
-0.74 (-0.99; 
-0.48), p < 
0.001 
0.16 (-0.14; 
0.47), p = 0.30 
NSAIDs and paracetamol (N = 39) 
CGI-BP 
overall 
4.5 ± 0.9 4.5 ± 0.9 4.6 ± 0.8 -0.05 (-0.06; 
-0.04), p < 
0.001 
-0.05 (-0.06; 
-0.04), p < 
0.001 
-0.05 (-0.06; 
-0.03), p < 
0.001 
0.0003 (-0.02; 
0.02), p = 0.97 
CGI-BP 
depression 
4.2 ± 1.1 4.2 ± 1.2 4.6 ± 0.9 -0.05 (-0.06; 
-0.04), p < 
0.001 
-0.05 (-0.06; 
-0.04), p < 
0.001 
-0.05 (-0.07; 
-0.03), p < 
0.001 
-0.003 (-0.025; 




3.0 ± 1.3 3.0 ± 1.3 3.2 ± 1.1 -0.03 (-
0.035; -








0.018), p < 
0.001 
-0.006 (-0.026; 
0.014), p = 
0.56 
BISS 56.6 ± 19.2 56.2 ± 20.1 63.2 ± 14.4 -0.87 (-0.96; 
-0.78), p < 
0.001 
-0.87 (-1.00; 
-0.73), p < 
0.001 
-0.96 (-1.24; 
-0.68), p < 
0.001 
-0.11 (-0.46; 
0.24), p = 0.54 
 
 
